Targos Molecular Pathology
Targos Molecular Pathology, founded in 2005 and headquartered in Kassel, Germany, provides standardized clinical biomarker research, development, and application services for hospitals and diagnostic laboratories worldwide in the histopathology services sector.
- Company typePrivate
- Founded2005
- HeadquartersKassel, Germany
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Targos Molecular Pathology does
Targos Molecular Pathology is a privately held, for-profit clinical biomarker services provider founded in 2005 and headquartered in Kassel, Germany, operating with a headcount of 101–250 employees. The company positions itself as offering a highly standardized environment for clinical biomarker research, development, and application, serving as a specialized services partner within the global histopathology and tissue diagnostics sector.
Its primary customer base consists of hospitals and diagnostic laboratories worldwide that utilize histopathology services for tissue analysis, disease identification, and characterization in clinical settings. Targos is identified as a key player in the global histopathology services market alongside competitors including TPL Path Labs, UNILABS, and Sonic Healthcare Limited. The addressable market is projected to grow from approximately US$23.89 billion in 2021 to US$35.19 billion by 2028 at a 5.7% CAGR, with growth driven by increasing cancer prevalence, demand for personalized medicine, and the adoption of digital pathology platforms, AI tools, and automated tissue processing technologies.
Detailed information regarding Targos' specific product portfolio, underlying technology stack, pricing model, go-to-market motion, geographic footprint beyond Germany, ownership structure, funding history, and named customers is not disclosed in the available source material. Source attribution is limited to a single market-research reference, and no company-level operational disclosures (revenue, M&A, leadership, certifications, or product launches) are available to triangulate further.
Targos Molecular Pathology firmographics
Firmographics- Name
- Targos Molecular Pathology
- Legal name
- Targos Molecular Pathology
- Website
- https://targos-gmbh.de
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Targos Molecular Pathology, founded in 2005 and headquartered in Kassel, Germany, provides standardized clinical biomarker research, development, and application services for hospitals and diagnostic laboratories worldwide in the histopathology services sector.
- Ownership category
- akta.pro rank
Targos Molecular Pathology industry classification
Industry- Product category
- Molecular Pathology Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Anatomic Pathology & Histopathology (Trial Support) (HLAGAEAC)
- akta.pro secondary industries
- Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA), Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)
Keywords
Where Targos Molecular Pathology is headquartered
LocationHeadquarters
- HQ city
- Kassel
- HQ country
- Germany
- HQ region
- Europe
Markets served
Targos Molecular Pathology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
Targos Molecular Pathology product offering
Product offeringCore offering
Targos Molecular Pathology provides a highly standardized environment for clinical biomarker research, development, and application. The company operates in the tissue diagnostics sector, offering histopathology and molecular pathology services to support disease identification, characterization, and personalized medicine initiatives for hospitals and diagnostic laboratories worldwide.
Product overview
No product and services information available for Targos Molecular Pathology in the provided source data.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Biomarker Research and Development Services Highly standardized environment for clinical biomarker research, development, and application supporting tissue-based diagnostic services for disease identification and characterization. Targeted at hospitals and diagnostic laboratories.
Companies that use Targos Molecular Pathology
Customer profileSegments1 record
Ideal customer profiles1 record
Targos Molecular Pathology technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Targos Molecular Pathology partnerships and signals
Strategic signalScale indicators1 record
Targos Molecular Pathology competitors and assessment
Company assessmentBroad incumbents
- Sonic Healthcare Limited: Global medical diagnostics and pathology incumbent listed in the same market report as Targos. Offers anatomic and molecular pathology services across many geographies at significantly larger scale.
- SYNLAB Group: Large European medical diagnostics services provider offering clinical laboratory and pathology services including histology and molecular diagnostics. Headquartered in Germany-adjacent Europe, directly relevant as a regional competitor.
- LabCorp Drug Development (now Fortrea): Major central laboratory offering biomarker, anatomic pathology and companion diagnostic services to global clinical trial sponsors. A scaled competitor for biomarker workflow work that Targos also targets.
Direct peers
- UNILABS: European-headquartered clinical diagnostics and pathology services provider explicitly named alongside Targos in the same histopathology market report. Overlaps directly in anatomic pathology and biomarker services for hospitals and clinical trial sponsors.
- Q² Solutions: Central laboratory and biomarker services provider for clinical trials, jointly backed by IQVIA. Directly comparable to Targos's standardized biomarker research and development environment for pharma sponsors.
- NeoGenomics: US-based specialty oncology / molecular pathology laboratory serving hospitals, pharma and clinical trial sponsors with biomarker assays. Comparable business model targeting the same oncology clinical trial customer base.
- Cerba HealthCare: European clinical diagnostics and specialty pathology network with strong central lab and biomarker capabilities. Competes with Targos for pharma and hospital pathology work across Europe.
- Discovery Life Sciences: Provides biospecimens and molecular pathology services including IHC, multiplex immunofluorescence, ISH, and digital pathology — directly comparable to Targos's biomarker and tissue-based diagnostics offering, especially for clinical trial sponsors.
- TPL Path Labs: Histopathology services provider named alongside Targos as a key player in the global histopathology services market. Direct overlap in tissue-based diagnostic and anatomic pathology services.
Emerging players
- Histo-Path Laboratories / Centrex Diagnostics: Specialized anatomic and molecular pathology laboratory serving community hospitals and oncology practices. Comparable specialty pathology focus though at a smaller scale and US-centric footprint.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights6 records
Customer concentration
Targos Molecular Pathology social profiles
Digital presenceTargos Molecular Pathology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Targos Molecular Pathology leadership team
Management profileNumber of profiles
Targos Molecular Pathology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Targos Molecular Pathology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Targos Molecular Pathology
What does Targos Molecular Pathology do?
Targos Molecular Pathology provides a highly standardized environment for clinical biomarker research, development, and application. The company operates in the tissue diagnostics sector, offering histopathology and molecular pathology services to support disease identification, characterization, and personalized medicine initiatives for hospitals and diagnostic laboratories worldwide.
When was Targos Molecular Pathology founded?
Targos Molecular Pathology was founded in 2005. It employs 101 to 250 people.
Where is Targos Molecular Pathology based?
Targos Molecular Pathology is headquartered in Kassel, Germany, in the Europe region.
Who are Targos Molecular Pathology's main competitors?
Broad incumbents on record are Sonic Healthcare Limited, SYNLAB Group and LabCorp Drug Development (now Fortrea). Direct peers are UNILABS, Q² Solutions, NeoGenomics, Cerba HealthCare, Discovery Life Sciences and TPL Path Labs. Histo-Path Laboratories / Centrex Diagnostics is listed as an emerging player.
Does Targos Molecular Pathology have an API?
No public API is recorded for Targos Molecular Pathology.
What industry is Targos Molecular Pathology in?
Targos Molecular Pathology's product category is Molecular Pathology Services. Its primary akta.pro industry code is HLAGAEAC, Anatomic Pathology & Histopathology (Trial Support), with a secondary code of HLAFAMAA, Anatomic Pathology (Histopathology & Cytopathology). Its NAICS code is 621511 and its SIC code is 8071.